Quality Assurance and Good Manufacturing Practices for Processing Hematopoietic Progenitor Cells
- 1 December 1995
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Hematotherapy
- Vol. 4 (6) , 493-501
- https://doi.org/10.1089/scd.1.1995.4.493
Abstract
Hematopoietic progenitor cell processing is now only a part of somatic cell and gene therapy. As these new therapies become used increasingly, it is essential that the new products used to treat patients be as safe and effective as possible. Although progenitor cell processing is still an evolving activity, it is appropriate to introduce standardization and product and process control into the routine laboratory activities. Initial suggestions for quality assurance and good manufacturing practices to accomplish this are presented here. These will need to be modified as experience is gained with progenitor, somatic cell, and gene therapy.Keywords
This publication has 10 references indexed in Scilit:
- The new generation of blood componentsTransfusion, 1995
- Error in medicineJAMA, 1994
- Maintenance of transplantation potential in ex vivo expanded CD34(+)- selected human peripheral blood progenitor cellsBlood, 1994
- Quality systems and total process control in blood bankingTransfusion, 1994
- Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapseBlood, 1994
- Using T Cells to Treat B-Cell CancersNew England Journal of Medicine, 1994
- Regulation of Somatic-Cell Therapy and Gene Therapy by the Food and Drug AdministrationNew England Journal of Medicine, 1993
- Large-scale expansion of human stem and progenitor cells from bone marrow mononuclear cells in continuous perfusion culturesBlood, 1993
- Gene therapy for cancerJAMA, 1992
- Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineageBlood, 1992